FluoroPharma Medical, Inc. announced that new Phase II data related to CardioPET (18-F FCPHA) for the assessment of myocardial perfusion and fatty acid uptake in coronary artery disease (CAD) patients was presented at the 19th Annual Scientific Session of ASNC, held this weekend, by the lead author of the abstract, Dr. Manuel Cerqueira. In responding to a question regarding a SPECT fatty acid tracer following the presentation, Dr. Cerqueira suggested that while there are no comparative data with these agents, PET with an F-18 label should provide higher image quality than a SPECT agent.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0001 USD | -50.00% | -.--% | -.--% |
2022 | FluoroPharma Medical, Inc. Announces Executive Changes | CI |
2022 | FluoroPharma Medical, Inc. Appoints Frank I Igwealor as CFO | CI |
1st Jan change | Capi. | |
---|---|---|
-.--% | 2.76K | |
+1.51% | 42.59B | |
+8.57% | 40.65B | |
+49.22% | 40.57B | |
-12.36% | 26.77B | |
+8.92% | 24.81B | |
-25.13% | 18.17B | |
+29.17% | 12.05B | |
-3.12% | 11.7B | |
+6.35% | 11.1B |
- Stock Market
- Equities
- FPMI Stock
- News FluoroPharma Medical, Inc.
- FluoroPharma Medical, Inc. Announces the Data from its Phase II Clinical Trial of 18-F FCPHA